Trial
NCT02780128
Next Generation Personalized Neuroblastoma Therapy
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Yael P Mosse
Collaborators
Novartis Pharmaceuticals; Foundation Medicine
Condition
Neuroblastoma
Intervention
Biopsy
Why stopped
The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-10